Belhaven Biopharma
Scott Lyman is currently serving as the Chief Executive Officer at Belhaven Biopharma, a company focused on developing dry powder nasal medicines for emergency treatments. Prior to this role, Scott held various leadership positions at companies such as Grid Therapeutics, BD, GlaxoSmithKline, BioCryst Pharmaceuticals, Salix Pharmaceuticals, Valeant Pharmaceuticals, and Amgen. Scott holds a degree in MBA in Corporate Finance & Entrepreneurship/Entrepreneurial Studies from UNC Kenan-Flagler Business School, a M.S. in Chemical Engineering from the University of Colorado Boulder, and a B.S. in Chemical Engineering from Iowa State University.
This person is not in any teams
Belhaven Biopharma
Belhaven Biopharma is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergency situations